Acetaminophen is one of the most common over-the-counter pain medications used worldwide and is considered safe at therapeutic dose. However, intentional and unintentional overdose accounts for up to 70% of acute liver failure cases in the western world. Extensive research has demonstrated that the induction of oxidative stress and mitochondrial dysfunction are central to the development of acetaminophen-induced liver injury. Despite the insight gained on the mechanism of acetaminophen toxicity, there still is only one clinically approved pharmacological treatment option, N-acetylcysteine. N-acetylcysteine increases the cell's antioxidant defense and protects liver cells from further acetaminophen-induced oxidative damage. Because it primarily protects healthy liver cells rather than rescuing the already injured cells alternative treatment strategies that target the latter cell population are warranted. In this study, we investigated mitochondria as therapeutic target for the development of novel treatment strategies for acetaminophen-induced liver injury. Characterization of the mitochondrial toxicity due to acute acetaminophen overdose in vitro in human cells using detailed respirometric analysis revealed that complex I-linked (NADH-dependent) but not complex II-linked (succinate-dependent) mitochondrial respiration is inhibited by acetaminophen. Treatment with a novel cell-permeable succinate prodrug rescues acetaminophen-induced impaired mitochondrial respiration. This suggests cell-permeable succinate prodrugs as a potential alternative treatment strategy to counteract acetaminophen-induced liver injury.
Introduction
Acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) is one of the most common over-the-counter medications used worldwide [1, 2] . APAP is considered safe at therapeutic dose but has been associated with acute liver injury and liver failure in cases of intentional and unintentional overdose. In the western world, APAP accounts for up to 70% of acute liver failure cases [1] [2] [3] [4] [5] . Central to the development of APAP-induced liver injury is the formation of reactive oxygen species (ROS) and depletion of glutathione [6] . As a result, oxidative stress damages cellular proteins, including mitochondrial proteins, which induces further oxidative stress [1, 2, 6] . Within recent years, the critical role of mitochondrial function in the development of APAP-induced liver injury has been well established, but details on the exact mechanism of APAP's mitochondrial toxicity still remain controversial [2, 3, [6] [7] [8] . In addition, the majority of research was done in rodent models and the number of ex vivo or in vivo human studies addressing the mechanism of APAP-induced hepatotoxicity and the role of mitochondrial dysfunction are limited [9, 10] . Despite the extensive research that has been performed to date on APAP-induced liver failure, the only clinically approved pharmacological treatment option for APAP intoxication is N-acetylcysteine (NAC). NAC replenishes glutathione levels, increases the cell's antioxidant defense and thus, protects from further oxidative damage induced by APAP. It is more of preventive rather than rescuing nature, with lesser benefit for the already damaged cells [5, 7, 11] . Therefore, alternative treatment strategies that target the already damage liver cells are warranted.
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In this this study, we investigated mitochondria as potential therapeutic target for treatment of APAP-induced liver injury in vitro. We first characterized the acute effect of APAP on mitochondrial function in primary human hepatocytes, HepG2 cells, and human platelets using respirometry. We then evaluated the efficacy of a cell-permeable succinate prodrug (NV241), a mitochondrially targeted alternative energy substrate, to rescue the impaired mitochondrial respiration following acute overdose of APAP.
Materials and methods

Materials
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany). The cell-permeable succinate prodrug NV241 was provided by NeuroVive Pharmaceutical AB (Lund, Sweden) [12] .
Human liver cells
Human plateable primary hepatocytes (male, Caucasian, 69 years of age) were acquired from ThermoFisher Scientific (Bleiswijk, Netherlands) and plated as previously described [13] .
The human hepatocyte carcinoma cell line HepG2 (male, Caucasian, 15 years of age) was purchased from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany). The cells were cultured at 37˚C and 5% CO 2 in minimum essential medium (MEM) (ThermoFisher Scientific, Bleiswijk, Netherlands) supplemented with 10% fetal bovine serum Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany), 1% non-essential amino acids, 2 mM L-glutamine, 50 μg � ml -1 streptomycin and 50 U � ml -1 penicillin (all ThermoFisher Scientific, Bleiswijk, Netherlands).
At 70-80% confluence, cells were collected using trypsin (0.05%, ThermoFisher Scientific, Bleiswijk, Netherlands), re-suspended in culture medium and counted using an automated cell counter (TC20™ Automated Cell Counter, Bio-Rad laboratories, Solna, Sweden) [13] .
Human platelets
The study was carried out in accordance with the Declaration of Helsinki. All blood cell experiments were performed with approval of the regional ethics committee of Lund University, Sweden (permit no. 2013/181). After written informed consent was acquired venous blood from healthy volunteers was drawn in K 2 EDTA tubes (Vacutainer1, BD, Franklin Lakes, USA) according to standard clinical practice. Human platelets were isolated and counted as previously described [14] .
Respirometry
Respiration of human primary hepatocytes was measured using the Seahorse XFe96 Analyzer (Agilent technologies, Massachusetts, USA). The day before the experiment, the primary hepatocytes were plated for four hours at 37˚C and 5% CO 2 at a cell density of 20 000 cells per well on collagen-coated 96-well plates (Agilent Seahorse XFe96 products, Agilent technologies, Waghaeusel-Wiesental, Germany). The plating medium was subsequently removed and replaced with culture medium of the same composition as for HepG2 cells. The cells were kept overnight at 37˚C and 5% CO 2 until use. Prior to the experiment the culture medium was replaced with XF-Base medium (Agilent Seahorse XF, Agilent technologies, Waghaeusel-Wiesental, Germany) containing 10 mM glucose, 2 mM L-glutamine and 5 mM sodium pyruvate (pH 7.4) and the cells were left to equilibrate for 1.5 hours at 37˚C and atmospheric O 2 and CO 2 until start of the respirometric protocol [13] . Mitochondrial respiration of the human carcinoma liver cell line HepG2 and of human platelets was measured with a high-resolution oxygraph (O2k, Oroboros Instruments, Innsbruck, Austria). Data were recorded using DatLab software versions 6 and 7 (Oroboros Instruments, Innsbruck, Austria) and respirometry was performed at 37˚C, with 2 mL active chamber volume and a stirrer speed of 750 rpm. Respirometry protocols with human platelets and HepG2 cells were performed in MiR05 medium (0.5 mM EGTA, 3 mM MgCl 2 , 60 mM Klactobionate, 20 mM Taurine, 10 mM KH 2 PO 4 , 20 mM HEPES, 110 mM sucrose and 1g/L bovine serum albumin) and all respiratory values were corrected for the oxygen solubility factor of the medium (0.92) [15] . Mitochondrial respiration was measured at cell concentrations of 200 x 10 6 platelets per mL and 0.5 x 10 6 HepG2 cells per mL [13, 14, 16, 17] .
Respirometric protocols for intact cells
The effect of APAP on mitochondrial respiration was first evaluated in intact human primary hepatocytes. Due to the restriction of 4 additions per sample in the Seahorse Analyzer increasing doses of APAP or vehicle were added to separate samples/wells. After routine respiration, the respiration dependent on oxidative phosphorylation of endogenous substrates, was measured, cells were exposed to vehicle (DMSO, control) or APAP (2.5, 5, 7.5 or 10 mM) for 15 min, followed by the addition of the protonophore carbonyl-cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP, 1 μM) which was added to uncouple the electron transport system (ETS) from the phosphorylation pathway and measure maximal respiration dependent on the ETS alone. This was followed by a simultaneous addition of rotenone (2 μM) and the cell-permeable succinate prodrug NV241 (250 μM) to evaluate if mitochondrial complexes downstream of complex I (CI) are affected by APAP and if the cell-permeable succinate prodrug NV241 can bypass APAP-induced inhibition of mitochondrial respiration. Non-mitochondrial respiration was measured by addition of the complex III (CIII) inhibitor antimycin A (1 μg � ml -1 ) and was subtracted from all respiratory values. Next, the translatability of the human liver carcinoma cell line HepG2 and human platelets to study drug-induced mitochondrial and organ-specific toxicity was evaluated. HepG2 cells and human platelets were re-suspended in MiR05 and routine respiration was measured. After routine respiration stabilized, increasing, accumulative doses of APAP or vehicle (DMSO, control) were added to each sample. After the highest dose of APAP (10 mM) or vehicle was given, CI-linked mitochondrial respiration was inhibited by rotenone (2 μM) and the cell-permeable succinate prodrug NV241 (250 μM) was added subsequently to investigate if mitochondrial complexes downstream of CI are affected by APAP and if the cell-permeable succinate prodrug NV241 can bypass APAP-induced inhibition of mitochondrial respiration. Nonmitochondrial respiration was measured by addition of antimycin A (1 μg � ml -1 ), which all respiratory values were corrected for.
Respirometric protocols for permeabilized cells
To further characterize the inhibitory effect of APAP on mitochondrial respiration, a substrate-uncoupler-inhibitor titration (SUIT) protocol was applied using HepG2 cells and human platelets. After routine respiration was measured, intact HepG2 cells and human platelets received either APAP (10 mM) or vehicle and were exposed for 10 min. Following the exposure, the plasma membrane was permeabilized using digitonin to allow substrates, which are otherwise impermeable, cellular access, followed by sequential additions of complex-specific substrates and inhibitors [17] . Platelets were permeabilized with 1 μg digitonin per 1 � 10 6 platelets [14] and HepG2 cells were permeabilized with 10 μg digitonin per 1 � 10 6 cells. The optimal digitonin concentrations were determined in separate experiments and found to induce maximal cell membrane permeabilization without disruption of mitochondrial respiration.
Respirometric protocol to evaluate the coupling potential of the cellpermeable succinate prodrug NV241
In human platelets, the effect of APAP (10 mM) or vehicle (DMSO, control) on routine respiration was evaluated for 10 min, followed by the addition of the cell-permeable succinate prodrug NV241 (250 μM) or its vehicle (DMSO, control). Subsequently, coupled mitochondrial respiration, the respiration coupled to phosphorylation by the ATP-synthase, was measured by and calculated as the difference before and after addition of the ATP-synthase inhibitor oligomycin (1 μg/ml) [18] . The respirometric protocol was completed by measuring non-mitochondrial respiration following the addition of the CI inhibitor rotenone (2 μM) and the CIIIinhibitor antimycin A (1 μg/ml), which all respiratory values were corrected for.
Data analysis
As the magnitude of change in the evaluated parameter was not pre-defined, power calculation for sample size was not applied. Experiments with HepG2 cells and human platelets were performed with a group size of six replicates and experiments with primary human hepatocytes were conducted with three separately prepared replicates of the same donor (each including � 4 technical replicates per group). Statistical analyses were performed using GraphPad Prism version 7 (GraphPad Software, Inc., La Jolla, California, USA). Data are presented as mean ± range or scatter plot and mean ± range. Because the baseline routine respiration of primary hepatocytes demonstrated more variation before start of exposure to APAP as compared to HepG2 cells and human platelets, quantification and data analysis was performed with data expressed as percentage (%) of routine respiration (first measurement of routine respiration). All other data are expressed as pmol O 2 × sec -1 × cell number -1 . Respiratory states measured by high-resolution respirometry of human platelets were previously found to be normally distributed [14] , justifying the use of parametric tests for the present study. Analyses of differences between �3 groups were performed by one-way ANOVA with Dunnet's (Fig 1) or Tukey's (Fig 7) multiple comparison test. Paired, two tailed student's t-test was used for comparison of two groups (Figs 2, 3, 5 and 6). The half maximal inhibitory concentrations (IC 50 ) were calculated by standard nonlinear curve fitting of normalized values (% of routine respiration, Fig 4) . A p-value of 0.05 or less was considered to indicate significant differences.
Results
Effect of acetaminophen on mitochondrial respiration of intact primary hepatocytes, HepG2 cells and human platelets
We first assessed the effect of APAP on mitochondrial respiration in intact human primary hepatocytes. Following exposure to APAP for 15 min routine respiration was dose- 
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Succinate prodrugs rescue mitochondrial respiration following acute acetaminophen overdose dependently decreased compared to control (Figs 1 and 4 ). Subsequent uncoupling of the electron transport from the phosphorylation pathway with FCCP to measure mitochondrial respiration related to the ETS alone also showed a dose-dependent decrease with APAP as compared to vehicle control ( Fig 1C) . To evaluate whether mitochondrial complexes downstream of CI would be affected by APAP and if a cell-permeable succinate prodrug can bypass APAP-induced inhibition of mitochondrial respiration, a simultaneous addition of rotenone and the cell-permeable succinate prodrug NV241 followed. While the magnitude of decrease in mitochondrial respiration in response to this addition differed between vehicle-treated and APAP-intoxicated cells (Fig 1A) , the respiration levels after the simultaneous addition of rotenone and NV241 were mostly similar between groups (Fig 1D) . The remaining complex II (CII)-linked mitochondrial respiration supported by the cell-permeable succinate prodrug NV241 (Fig 1D) showed a minor difference between control and APAP-treated primary hepatocytes at the lowest dose tested (2.5 mM, p<0.05) but no effect at higher doses, indicating a lack of dose-dependency.
Next, we assessed the suitability of the human hepatocyte carcinoma cell line HepG2 for indepth characterization of the mitochondrial inhibition in liver cells induced by APAP. Similar to primary human hepatocytes, routine respiration supported by endogenous substrates decreased dose-dependently following exposure to APAP (Figs 2A and 4) . At a dose of 10 mM, routine respiration was significantly reduced by 60% compared to vehicle control (p<0.01) (Fig 2B) . After addition of APAP, CI was inhibited with rotenone to subsequently measure CII-linked mitochondrial respiration in the presence of the cell-permeable succinate prodrug NV241 and isolated from any effects of APAP on CI and to additionally evaluate the ability of NV241 to bypass APAP-induced mitochondrial dysfunction. Addition of NV241 resulted in similar levels of CIIlinked mitochondrial respiration in vehicle controls and APAP-intoxicated cells (Fig 2C) .
We then evaluated the translatability of human platelets as surrogate tissue to study APAP's effect on mitochondrial function, using the same protocol as described for HepG2 cells. As primary, non-cultured human cells, human platelets from healthy donors present a source of viable, fresh mitochondria. In intact human platelets, routine respiration supported by endogenous substrates was likewise reduced dose-dependently in response to APAP (Figs 3A and 4). At the highest dose, APAP (10 mM) reduced routine respiration by 52% compared to vehicle control (p<0.001) (Fig 3B) . We continued the protocol with the addition of rotenone followed by the cell-permeable succinate prodrug NV241. Like in primary human hepatocytes and HepG2 cells, treatment with the cell-permeable succinate prodrug NV241 resulted in similar levels of respiration in vehicle controls and APAP-intoxicated cells (Fig 3C) .
Despite differences in routine respiration before exposure, the sensitivity to inhibition by APAP was similar between the three cell types, with primary hepatocytes demonstrating a slightly lower IC 50 value than HepG2 cells and human platelets (primary hepatocytes: IC 50 6.0 mM, HepG2 cells: IC 50 : 6.6 mM and human platelets: IC 50 : 7.4 mM, Fig 4) . This demonstrates that HepG2 cells and human platelets are suitable cellular models for further evaluation of the inhibition of mitochondrial respiration by APAP.
Characterization of the inhibition of mitochondrial respiration in HepG2 cells and human platelets
Further in-depth characterization of the inhibitory effect of APAP on mitochondrial respiration was performed using a Substrate-Uncoupler-Inhibitor-Titration (SUIT) protocol. After exposure to APAP (10 mM) for 10 min, intact platelets or HepG2 cells were permeabilized using digitonin, which was followed by sequential additions of complex-specific substrates and inhibitors at saturating concentrations to allow measurements of maximal respiratory capacities. Representative traces of simultaneously measured respiration of vehicle-treated and APAP-treated HepG2 cells are illustrated in Fig 5A .
In HepG2 cells, maximal CI-linked, ADP-stimulated mitochondrial respiration in the presence of the substrates malate, pyruvate, and glutamate (OXPHOS CI-linked ) was significantly decreased by 66% in APAP-treated cells (p<0.001) (Fig 5A and 5B) . Despite decreased OXPHOS CI-linked respiration, convergent complex I+II (CI+II)-linked, maximal ADP-stimulated mitochondrial respiration in the presence of malate, pyruvate, glutamate, and succinate (OXPHOS CI+II-linked ) was unchanged in APAP-intoxicated HepG2 cells as compared to control (Fig 5A and 5C ). Both maximal convergent CI+CII-and CII-linked mitochondrial respiration dependent on the ETS alone were unaffected in HepG2 cells by APAP (S1 Fig) . In human platelets, maximal CI-linked and convergent CI+II-linked, ADP-stimulated mitochondrial respiration, as well as maximal convergent CI+II-linked respiration dependent on the ETS alone was reduced following exposure to APAP: OXPHOS CI-linked (p<0.01, Fig 6A) , OXPHOS CI+II-linked (p<0.01, Fig 6B) and ETS CI+II-linked (p<0.01, Fig 6C) , respectively. Like in HepG2 cells, maximal CII-linked respiration dependent on the ETS alone (ETS CII-linked ) remained unaffected by APAP (Fig 6D) .
Treatment effect of a cell-permeable succinate prodrug on acetaminopheninduced inhibition of mitochondrial respiration
Lastly, we evaluated if the normalization of mitochondrial respiration by this novel pharmacological treatment strategy is linked to phosphorylation activity by the ATP-synthase. This was evaluated in intact human platelets following exposure to APAP (10 mM) for 10 min, with and without subsequent treatment, and calculated as the difference in respiration before and after the inhibition of the ATP-synthase. Mitochondrial respiration coupled to phosphorylation by the ATP-synthase, here referred to as coupled respiration, was decreased by 40% (p<0.01) by APAP (Fig 7) . Treatment with the cell-permeable succinate prodrug NV241 rescued coupled respiration and restored it to the level of controls (Fig 7) .
Discussion
In this study, we demonstrated that APAP induces an immediate inhibition of mitochondrial respiration in human-derived cells through interference with CI or upstream metabolism while respiration associated with CII and downstream complexes remains unaffected. The toxicity profile of APAP on mitochondrial respiration was not exclusive to hepatic cells and was confirmed in fresh human platelets, presenting them as suitable surrogate tissue to study the role of mitochondrial dysfunction in acute APAP-induced toxicity. Treatment with a cellpermeable succinate prodrug normalized the drug-induced impairment of mitochondrial respiration, demonstrating the ability of succinate to bypass APAP-induced mitochondrial dysfunction and presenting cell-permeable succinate as a potential novel pharmacological treatment strategy for APAP-induced liver injury. APAP is the main cause for acute liver failure in the western world and, with a mortality rate of 0.4%, not uncommonly ends fatally [1] [2] [3] [4] . The critical role of mitochondrial dysfunction in the development of APAP-induced liver injury and failure has been previously reported by others [2, 3, 6, 7, 9, 10, 19] . Inhibition of the respiratory chain, induction of mitochondrial permeability transition, increased mitochondrial oxidative stress, decreased mitochondrial ATP production and increased mitophagy has been associated with APAP overdose [2, 3, 6, 7] . In this study, we demonstrated that APAP induces mitochondrial toxicity through or https://doi.org/10.1371/journal.pone.0231173.g005 generated intracellularly at excessive amounts when the APAP-induced oxidative stress has depleted cellular glutathione. Independent of the origin of the toxic species, CII or downstream complexes were left mostly unaffected. The effect on CII-linked mitochondrial respiration observed in primary hepatocytes did not follow a dose-response pattern as only the lowest concentration of APAP tested showed a minor reduction of respiration. Therefore, the observed reduced CII-linked mitochondrial respiration in primary hepatocytes is likely unspecific and not related to APAP. Currently, the only clinically approved pharmacological treatment option for APAP overdose is NAC. NAC replenishes glutathione levels which increases the cell's ability to scavenge ROS. Thus, it protects liver cells from further APAP-induced oxidative injury [1, 5, 22] . Already damaged liver cells, however, benefit little from NAC treatment. Therefore, alternative treatment strategies are needed that can rescue the already damaged liver cells and prevent the resulting acute liver failure. At the preclinical stage, a limited number of mitochondrial targeted treatment strategies have shown success. The most promising pharmacological strategy, a mitochondrial-targeted antioxidant, decreased the magnitude of liver injury in mouse models of late-stage presenting APAP intoxication by reducing mitochondrial-related ROS production [7, 22, 23] . In this study, we demonstrated that CII-linked mitochondrial metabolism of a cell-permeable succinate prodrug can bypass and compensate for the decreased CIlinked mitochondrial metabolism following acute APAP exposure. These findings point towards a novel alternative treatment strategy for APAP-induced liver failure: mitochondrialtargeted, cell-permeable succinate prodrugs. Supplementation of an alternative energy source that liver cells can utilize despite the inhibitory effect of APAP on CI-linked metabolism could potentially allow them to maintain the required level of energy production and thus, rescue already injured liver cells. Succinate treatment has previously demonstrated by others to improve bioenergetics and reduce cell death in vitro in models of traumatic brain injury, metformin-induced and oxidant-induced mitochondrial dysfunction [24] [25] [26] , thus, further supporting this hypothesis. The cell-permeable succinate prodrug presented in this study is the lead candidate of the first generation of an extensive rational drug design program focused around Krebs cycle intermediates for treatment of mitochondrial dysfunction and related disorders. The succinate prodrug has improved cell-membrane permeability over succinate and has shown to release succinate intracellularly, bypass mitochondrial complex I-related dysfunction and support oxidative phosphorylation [12, 18, 27] . Because NV241 lacks sufficient stability in plasma and serum containing media, we were not able to investigate its treatment effect on long-term cellular effects caused by APAP or in vivo. Currently, compounds which are more stable and suitable for in vivo use are under development for future studies [28] .
Succinate has primarily been known as a metabolite of the TCA cycle. Over time, it has emerged to play a role in epigenetics, cell proliferation, paracrine signaling, ROS formation through reversed electron transport (RET) and inflammation [29] [30] [31] . While the risk of increased ROS through RET is low in the presence of CI inhibition [32] , the role of succinate in inflammation, especially during APAP-induced liver damage, needs to be further investigated. In the liver, succinate has been shown to contribute to activation of hepatic stellate cells and Kupffer cells, which phagocytose dead and apoptotic parenchymal cells but also send out pro-inflammatory signals and thus, potentially further aggravate APAP-induced liver injury https://doi.org/10.1371/journal.pone.0231173.g007 [30, 33] . Whether a succinate-induced pro-inflammatory response would aggravate APAPinduced liver injury or stimulate tissue repair pathways remains to be elucidated [30, 34] . In this study, human platelets and the human carcinoma liver cell line HepG2 were used as surrogate tissues to study the effect of APAP on mitochondrial respiration as well as the rescue effect of NV241 in acute APAP intoxication. The translatability between human platelets and tissue specific cell lines is continuously reevaluated. Human platelets, a fresh source of viable mitochondria, have been described to rely on oxidative phosphorylation and reflect mitochondrial function of other, more metabolically active tissues [35] [36] [37] [38] . Also cancer cells, long believed to rely solely on glycolysis, have now been described to upregulate their mitochondrial metabolism under certain conditions and rely on mitochondrial function for several cancerogenic processes [39, 40] . Even though there are important differences between primary hepatocytes, HepG2 cells and human platelets, our data indicate that they show a relative comparable sensitivity towards drug-induced mitochondrial dysfunction, as indicated by the similar IC 50 values determined in this study. Our data therefore present these cell types as suitable surrogate tissues to study the role of mitochondrial dysfunction in drug-induced toxicity and further indicate that the liver specific toxicity in patients with acute APAP intoxication is likely due to the first-pass metabolism of APAP instead of liver specific metabolism of the drug.
In conclusion, in this study we demonstrated, using human-derived cells, that APAP induces mitochondrial inhibition through CI (or upstream thereof) while CII and downstream complexes are unaffected. We further showed that a cell-permeable succinate prodrug normalizes APAP-induced inhibition of mitochondrial respiration, presenting pharmacological bypass of APAP-induced mitochondrial toxicity with cell-permeable succinate prodrugs as a promising alternative treatment strategy for APAP-induced mitochondrial dysfunction and, potentially, liver injury. 
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